Lakewood-Amedex Advances Nu-3 Toward Phase 2 Trials with $7.5M Capital Boost
Event summary
- Lakewood-Amedex listed on Nasdaq Capital Market under ticker LABT on April 23, 2026
- Raised $7.5M through Series C convertible preferred stock placement
- Positive preclinical safety data supports Phase 2a trial initiation for Nu-3 Gel in infected diabetic foot ulcers
- Expanded IP portfolio to 72 granted patents and 29 pending patents
- David G. Armstrong appointed as Study Chair and Scientific Advisor for Phase 2a clinical program
The big picture
Lakewood-Amedex's transition to a Nasdaq-listed company and $7.5M capital raise positions it to advance Nu-3, a potential treatment for infected diabetic foot ulcers, into Phase 2a trials. The company's focus on antimicrobial resistance aligns with growing industry concerns over multidrug-resistant pathogens. Success in these trials could validate the broader Bisphosphocin® platform, potentially opening avenues for addressing other serious infectious diseases.
What we're watching
- Clinical Validation
- Whether Nu-3 can demonstrate differentiated efficacy in Phase 2a trials against infected diabetic foot ulcers
- Financial Flexibility
- How the $7.5M capital raise will support Lakewood-Amedex through Phase 2a and potential future trials
- IP Strategy
- The pace at which Lakewood-Amedex can expand its patent portfolio to protect its Bisphosphocin® platform
Related topics